Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of repeat IV serelaxin dosing in chronic heart failure
2013-002781-39Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2014
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, double-blind trial of serelaxin in chronic heart failure (CHF), sponsored by Novartis. Primary endpoint: Primary: development of anti-serelaxin antibodies. Started Feb 2014; status: completed.
02
Drugs
serelaxin
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on 2013-002781-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002781-39.